hVIVO (LON:HVO) Stock Price Down 46.3% - Here's Why

hVIVO plc (LON:HVO - Get Free Report) shares fell 46.3% during mid-day trading on Friday . The company traded as low as GBX 6.50 ($0.09) and last traded at GBX 8.70 ($0.12). 83,062,000 shares traded hands during mid-day trading, an increase of 2,325% from the average session volume of 3,424,608 shares. The stock had previously closed at GBX 16.20 ($0.22).

Analyst Upgrades and Downgrades

Separately, Shore Capital restated a "buy" rating on shares of hVIVO in a research report on Friday.

hVIVO Stock Down 46.3%

The firm has a market cap of £61.56 million, a price-to-earnings ratio of 3.59 and a beta of 0.97. The stock's 50 day moving average is GBX 16.16 and its 200 day moving average is GBX 18.13. The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86.

hVIVO (LON:HVO - Get Free Report) last issued its quarterly earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share (EPS) for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. Analysts forecast that hVIVO plc will post 1.5492958 EPS for the current year.

Insider Activity at hVIVO

In other hVIVO news, insider Yamin Mo' Khan sold 3,062,246 shares of the company's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.23), for a total value of £520,581.82 ($700,459.93). Company insiders own 14.03% of the company's stock.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.